A Wall Street analyst issued contrasting ratings on Tuesday for two major diagnostic testing companies, upgrading shares of ...

Shares of Quest Diagnostics Inc. DGX slid 1.71% to $172.01 Wednesday, on what proved to be an all-around positive trading ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

Fintel reports that on March 4, 2025, Citigroup downgraded their outlook for Quest Diagnostics (NYSE:DGX) from Buy to Neutral ...

Charles River Labs (CRL) stock and LabCorp (LH) stock were upgraded and Quest Diagnostics (DGX) stock was downgraded at Citi.

Citi downgraded Quest Diagnostics (DGX) to Neutral from Buy with an unchanged price target of $185. The firm believes Quest is well positioned ...

Fresenius Medical Care's parent company sells 10.6 million shares, the proceeds of which will be used to reduce its leverage and achieve higher profits in 2025.

Quest Diagnostics DGX has achieved impressive growth over the past year, with its shares rising 38%. It has outperformed the industry’s 7.7% rise and the S&P 500 composite’s 17.1% gain.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Fresenius Medical Care plans to sell select assets of Spectra Laboratories to Quest Diagnostics as it exits non-core markets.

In an age of capitation and value-based care, health plans must work harder than ever to offer tailored support to higher-risk members with chronic conditions.

Shares of Quest Diagnostics Inc. DGX shed 1.10% to $175.01 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 1.22% to 5,778.15 ...